Core Insights - Serina Therapeutics is making significant progress in developing its proprietary POZ Platform for drug optimization, particularly focusing on SER-252 for advanced Parkinson's care [2][3] - The company has secured $15 million in equity financing, enhancing its financial foundation to support ongoing clinical trials and research initiatives [7] - Recent data presented at a summit indicates that Serina's POZ-lipid technology may lead to safer and more effective lipid nanoparticle formulations for gene therapy [7] Recent Highlights - The company is on track to dose the first patient in the Phase 1b clinical trial of SER-252 by Q4 2025 [6] - Two experienced biotech leaders have been added to the Board of Directors, enhancing corporate strategy and business development capabilities [7] - The POZ Platform is being advanced across multiple therapeutic modalities, including neurological disorders and RNA-based therapeutics [2][7] First Quarter Operating Results - Revenues for Q1 2025 were not material, similar to Q1 2024 [4] - Operating expenses increased to $5.9 million in Q1 2025 from $2.3 million in Q1 2024, driven by higher R&D and administrative costs [4][6] - R&D expenses rose to $3.0 million in Q1 2025, up from $1.1 million in Q1 2024, primarily due to increased headcount and professional fees [5] Financial Performance - The net loss for Q1 2025 was $4.8 million, or $(0.49) per share, compared to a net loss of $15.0 million, or $(5.38) per share, in Q1 2024 [10][22] - Other income for Q1 2025 was $1.0 million, a significant improvement from a net expense of $12.7 million in Q1 2024 [9][22] - Cash and cash equivalents totaled $4.3 million as of March 31, 2025, with projections indicating sufficient funds to last through Q3 2025 [11] Liquidity Information - The company has a strengthened balance sheet following recent financing, which includes a $10 million investment from JuvVentures and a $5 million private placement [7][11] - Total current assets as of March 31, 2025, were $5.8 million, with total liabilities at $5.2 million [20][21]

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT. A live webcast of the fireside chat style presentation will be accessible to registered attendees via the following link: https://us02web.zoom. ...

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clini ...

Core Points - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing its proprietary POZ Platform™ for drug optimization [3] - The CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025 [1] - The company is headquartered in Huntsville, Alabama, and is developing a pipeline of drug candidates for neurological diseases and other indications [3] Company Overview - Serina Therapeutics is developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other conditions [3] - The POZ Platform™ has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [3] - The company operates from the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama [3] Event Information - A live webcast of the CEO's presentation will be available for registered attendees, with an archived replay accessible for 90 days post-event [2]